Bordetella vaccines comprising LPS with reduced reactogenicity

A genetically modified Bordetella pertussis, Bordetella parapertussis or Bordetella bronchiseptica bacterium,

• wherein the bacterium is modified compared to the wild-type Bordetella pertussis, Bordetella parapertussis or Bordetella bronchiseptica bacterium in that it has a genetic modification that introduces a heterologous acyl transferase activity,
• wherein the genetic modification that introduces heterologous acyl transferase activity confers to the cell at least one of a heterologous LpxA, LpxL and LpxD acyl transferase activity and wherein the genetic modification introduces the expression of at least one of a heterologous LpxA, a LpxL, and a LpxD acyl transferase, wherein
• i) the LpxA acyl transferase has SEQ ID NO:
• 1, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 1;
• ii) the LpxL acyl transferase has SEQ ID NO:
• 2, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 2;
• and/or
• iii) the LpxD acyl transferase has SEQ ID NO:
• 4, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 4,
• wherein expression of the heterologous acyl transferase results in a B. pertussis, B. parapertussis or B. bronchiseptica LPS having a lipid A moiety that is modified as compared to the lipid A moiety of a wild-type B. pertussis, B. parapertussis or B. bronchiseptica LPS in that the length of at least one acyl chain is shorter and wherein the length of the acyl chain at the 3 position of the modified lipid A moiety does not have a greater length than the acyl chain of the wild-type B. pertussis, B. parapertussis or B. bronchiseptica lipid A moiety at the same 3 position.